Updates in diabetic peripheral neuropathy

F1000Research

Volumn 5, Issue , 2016, Pages

  Juster Switlyk, Kelsey ^a   Smith, A Gordon ^a  

^a UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALDOSE REDUCTASE INHIBITOR; AMITRIPTYLINE; DULOXETINE; GABAPENTIN; GLUCOSE; HEMOGLOBIN A1C; INSULIN; NORTRIPTYLINE; OPIATE; OXYCODONE; PARACETAMOL; PREGABALIN; THIOCTIC ACID; TRAMADOL; VENLAFAXINE;

ALLODYNIA; CLINICAL FEATURE; CLINICAL TRIAL (TOPIC); CONFOCAL MICROSCOPY; DIABETIC NEUROPATHY; DISEASE COURSE; DISEASE SEVERITY; DRUG APPROVAL; DRUG COST; DRUG EFFICACY; DRUG RESPONSE; DRUG TREATMENT FAILURE; ELECTRODIAGNOSIS; EXERCISE; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HUMAN; HYPERALGESIA; HYPERGLYCEMIA; INSULIN DEPENDENT DIABETES MELLITUS; MEDICAL HISTORY; MULTICENTER STUDY (TOPIC); NERVE REGENERATION; NEUROLOGIC EXAMINATION; NON INSULIN DEPENDENT DIABETES MELLITUS; PATHOGENESIS; PHYSIOTHERAPY; PREVALENCE; REVIEW; RISK ASSESSMENT; RISK FACTOR; SENSORY DYSFUNCTION; SKIN BIOPSY;

EID: 84978492503     PISSN: 20461402     EISSN: 1759796X     Source Type: Journal    
DOI: 10.12688/f1000research.7898.1     Document Type: Review

References (52)

1. Hossain P Kawar B El Nahas M: Obesity and diabetes in the developing world--a growing challenge. N Engl J Med. 2007;356(3):213-5. 17229948 10.1056/NEJMp068177
2. Singh R Kishore L Kaur N: Diabetic peripheral neuropathy: current perspective and future directions. Pharmacol Res. 2014;80:21-35. 24373831 10.1016/j.phrs.2013.12.005 F1000 Recommendation
3. Boulton AJ: Management of Diabetic Peripheral Neuropathy. Clin Diabetes. 2005;23(1):9-15. 10.2337/diaclin.23.1.9
4. Tesfaye S Selvarajah D: Advances in the epidemiology, pathogenesis and management of diabetic peripheral neuropathy. Diabetes Metab Res Rev. 2012;28(Suppl 1):8-14. 22271716 10.1002/dmrr.2239
5. Tesfaye S Vileikyte L Rayman G: Painful diabetic peripheral neuropathy: consensus recommendations on diagnosis, assessment and management. Diabetes Metab Res Rev. 2011;27(7):629-38. 21695762 10.1002/dmrr.1225
6. Tesfaye S Boulton AJ Dyck PJ: Diabetic neuropathies: update on definitions, diagnostic criteria, estimation of severity, and treatments. Diabetes Care. 2010;33(10):2285-93. 20876709 10.2337/dc10-1303 2945176
7. Quattrini C Tesfaye S: Understanding the impact of painful diabetic neuropathy. Diabetes Metab Res Rev. 2003;19(Suppl 1):S2-8. 12577252 10.1002/dmrr.360
8. Callaghan BC Cheng HT Stables CL: Diabetic neuropathy: clinical manifestations and current treatments. Lancet Neurol. 2012;11(6):521-34. 22608666 10.1016/S1474-4422(12)70065-0 4254767
9. Argoff CE Cole BE Fishbain DA: Diabetic peripheral neuropathic pain: clinical and quality-of-life issues. Mayo Clin Proc. 2006;81(4 Suppl):S3-11. 16608048 10.1016/S0025-6196(11)61474-2
10. Sadosky A Mardekian J Parsons B: Healthcare utilization and costs in diabetes relative to the clinical spectrum of painful diabetic peripheral neuropathy. J Diabetes Complications. 2015;29(2):212-7. 25498300 10.1016/j.jdiacomp.2014.10.013 F1000 Recommendation
11. American Diabetes Association: Economic costs of diabetes in the U.S. in 2012. Diabetes Care. 2013;36(4):1033-46. 23468086 10.2337/dc12-2625 3609540 F1000 Recommendation
12. Gordois A Scuffham P Shearer A: The health care costs of diabetic peripheral neuropathy in the US. Diabetes Care. 2003;26(6):1790-5. 12766111 10.2337/diacare.26.6.1790
13. Bansal V Kalita J Misra UK: Diabetic neuropathy. Postgrad Med J. 2006;82(964):95-100. 16461471 10.1136/pgmj.2005.036137 2596705
14. Tracy JA Dyck PJ: The spectrum of diabetic neuropathies. Phys Med Rehabil Clin N Am. 2008;19(1):1-26, v. 18194747 10.1016/j.pmr.2007.10.010 2720624
15. Gibbons CH Freeman R: Treatment-induced diabetic neuropathy: a reversible painful autonomic neuropathy. Ann Neurol. 2010;67(4):534-41. 20437589 10.1002/ana.21952 3057039 F1000 Recommendation
16. Ellenberg M: Diabetic neuropathic cachexia. Diabetes. 1974;23(5):418-23. 4364389 10.2337/diab.23.5.418
17. Tran C Philippe J Ochsner F: Acute painful diabetic neuropathy: an uncommon, remittent type of acute distal small fibre neuropathy. Swiss Med Wkly. 2015;145:w14131. 25941879 10.4414/smw.2015.14131 F1000 Recommendation
18. Tesfaye S Malik R Harris N: Arterio-venous shunting and proliferating new vessels in acute painful neuropathy of rapid glycaemic control (insulin neuritis). Diabetologia. 1996;39(3):329-35. 8721779 10.1007/s001250050449
19. Bril V Tomioka S Buchanan RA: Reliability and validity of the modified Toronto Clinical Neuropathy Score in diabetic sensorimotor polyneuropathy. Diabet Med. 2009;26(3):240-6. 19317818 10.1111/j.1464-5491.2009.02667.x 2871179
20. Rosenberg NR Portegies P de Visser M: Diagnostic investigation of patients with chronic polyneuropathy: evaluation of a clinical guideline. J Neurol Neurosurg Psychiatry. 2001;71(2):205-9. 11459893 10.1136/jnnp.71.2.205 1737522
21. Dyck PJ Overland CJ Low PA: Signs and symptoms versus nerve conduction studies to diagnose diabetic sensorimotor polyneuropathy: Cl vs. NPhys trial. Muscle Nerve. 2010;42(2):157-64. 20658599 10.1002/mus.21661 2956592
22. Smith AG Singleton JR: The diagnostic yield of a standardized approach to idiopathic sensory-predominant neuropathy. Arch Intern Med. 2004;164(9):1021-5. 15136313 10.1001/archinte.164.9.1021
23. Shtein RM Callaghan BC: Corneal confocal microscopy as a measure of diabetic neuropathy. Diabetes. 2013;62(1):25-6. 23258907 10.2337/db12-1114 3526060
24. England JD Gronseth GS Franklin G: Practice Parameter: evaluation of distal symmetric polyneuropathy: role of laboratory and genetic testing (an evidence-based review). Report of the American Academy of Neurology, American Association of Neuromuscular and Electrodiagnostic Medicine, and American Academy of Physical Medicine and Rehabilitation. Neurology. 2009;72(2):185-92. 19056666 10.1212/01.wnl.0000336370.51010.a1
25. England JD Gronseth GS Franklin G: Practice parameter: the evaluation of distal symmetric polyneuropathy: the role of autonomic testing, nerve biopsy, and skin biopsy (an evidence-based review). Report of the American Academy of Neurology, the American Association of Neuromuscular and Electrodiagnostic Medicine, and the American Academy of Physical Medicine and Rehabilitation. PM R. 2009;1(1):14-22. 19627868 10.1016/j.pmrj.2008.11.011
26. Beulens JW Hart HE Kuijs R: Influence of duration and dose of metformin on cobalamin deficiency in type 2 diabetes patients using metformin. Acta Diabetol. 2015;52(1):47-53. 24908579 10.1007/s00592-014-0597-8 F1000 Recommendation
27. Zilliox L Russell JW: Treatment of diabetic sensory polyneuropathy. Curr Treat Options Neurol. 2011;13(2):143-59. 21274758 10.1007/s11940-011-0113-1 3099261
28. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group. N Engl J Med. 1993;329(14):977-86. 8366922 10.1056/NEJM199309303291401
29. Linn T Ortac K Laube H: Intensive therapy in adult insulin-dependent diabetes mellitus is associated with improved insulin sensitivity and reserve: a randomized, controlled, prospective study over 5 years in newly diagnosed patients. Metabolism. 1996;45(12):1508-13. 8969284 10.1016/S0026-0495(96)90180-8
30. Duckworth W Abraira C Moritz T: Glucose control and vascular complications in veterans with type 2 diabetes. N Engl J Med. 2009;360(2):129-39. 19092145 10.1056/NEJMoa0808431 F1000 Recommendation
31. Ismail-Beigi F Craven T Banerji MA: Effect of intensive treatment of hyperglycaemia on microvascular outcomes in type 2 diabetes: an analysis of the ACCORD randomised trial. Lancet. 2010;376(9739):419-30. 20594588 10.1016/S0140-6736(10)60576-4 4123233 F1000 Recommendation
32. Callaghan BC: The Impact of the Metabolic Syndrome on Neuropathy. Reference Source
33. Tesfaye S Stevens LK Stephenson JM: Prevalence of diabetic peripheral neuropathy and its relation to glycaemic control and potential risk factors: the EURODIAB IDDM Complications Study. Diabetologia. 1996;39(11):1377-84. 8933008 10.1007/s001250050586
34. Tesfaye S Chaturvedi N Eaton SE: Vascular risk factors and diabetic neuropathy. N Engl J Med. 2005;352(4):341-50. 15673800 10.1056/NEJMoa032782
35. Callaghan B Feldman E: The metabolic syndrome and neuropathy: therapeutic challenges and opportunities. Ann Neurol. 2013;74(3):397-403. 23929529 10.1002/ana.23986 3881591 F1000 Recommendation
36. Cameron NE Eaton SE Cotter MA: Vascular factors and metabolic interactions in the pathogenesis of diabetic neuropathy. Diabetologia. 2001;44(11):1973-88. 11719828 10.1007/s001250100001
37. Malik RA Tesfaye S Thompson SD: Endoneurial localisation of microvascular damage in human diabetic neuropathy. Diabetologia. 1993;36(5):454-9. 8314451 10.1007/BF00402283
38. Callaghan BC Hur J Feldman EL: Diabetic neuropathy: one disease or two? Curr Opin Neurol. 2012;25(5):536-41. 22892951 10.1097/WCO.0b013e328357a797 4239661
39. Smith AG Russell J Feldman EL: Lifestyle intervention for pre-diabetic neuropathy. Diabetes Care. 2006;29(6):1294-9. 16732011 10.2337/dc06-0224 F1000 Recommendation
40. Balducci S Iacobellis G Parisi L: Exercise training can modify the natural history of diabetic peripheral neuropathy. J Diabetes Complications. 2006;20(4):216-23. 16798472 10.1016/j.jdiacomp.2005.07.005
41. Singleton JR Marcus RL Jackson JE: Exercise increases cutaneous nerve density in diabetic patients without neuropathy. Ann Clin Transl Neurol. 2014;1(10):844-9. 25493275 10.1002/acn3.125 4241811
42. Stevens JA Phelan EA: Development of STEADI: a fall prevention resource for health care providers. Health Promot Pract. 2013;14(5):706-14. 23159993 10.1177/1524839912463576 4707651
43. Ziegler D Low PA Litchy WJ: Efficacy and safety of antioxidant treatment with α-lipoic acid over 4 years in diabetic polyneuropathy: the NATHAN 1 trial. Diabetes Care. 2011;34(9):2054-60. 21775755 10.2337/dc11-0503 3161301
44. Oyenihi AB Ayeleso AO Mukwevho E: Antioxidant strategies in the management of diabetic neuropathy. Biomed Res Int. 2015;2015:515042. 25821809 10.1155/2015/515042 4363503 F1000 Recommendation
45. Hotta N Akanuma Y Kawamori R: Long-term clinical effects of epalrestat, an aldose reductase inhibitor, on diabetic peripheral neuropathy: the 3-year, multicenter, comparative Aldose Reductase Inhibitor-Diabetes Complications Trial. Diabetes Care. 2006;29(7):1538-44. 16801576 10.2337/dc05-2370
46. Bril V Buchanan RA: Long-term effects of ranirestat (AS-3201) on peripheral nerve function in patients with diabetic sensorimotor polyneuropathy. Diabetes Care. 2006;29(1):68-72. 16373898 10.2337/diacare.29.01.06.dc05-1447
47. Chalk C Benstead TJ Moore F: Aldose reductase inhibitors for the treatment of diabetic polyneuropathy. Cochrane Database Syst Rev. 2007; (4):CD004572. 17943821 10.1002/14651858.CD004572.pub2
48. Fraser DA Diep LM Hovden IA: The effects of long-term oral benfotiamine supplementation on peripheral nerve function and inflammatory markers in patients with type 1 diabetes: a 24-month, double-blind, randomized, placebo-controlled trial. Diabetes Care. 2012;35(5):1095-7. 22446172 10.2337/dc11-1895 3329837
49. Griebeler ML Morey-Vargas OL Brito JP: Pharmacologic interventions for painful diabetic neuropathy: An umbrella systematic review and comparative effectiveness network meta-analysis. Ann Intern Med. 2014;161(9):639-49. 25364885 10.7326/M14-0511 F1000 Recommendation
50. Callaghan BC Feldman EL: Painful diabetic neuropathy: many similarly effective therapies with widely dissimilar costs. Ann Intern Med. 2014;161(9):674-5. 25364890 10.7326/M14-2157
51. Iyer S Tanenberg RJ: Pharmacologic management of diabetic peripheral neuropathic pain. Expert Opin Pharmacother. 2013;14(13):1765-75. 23800105 10.1517/14656566.2013.811490
52. Callaghan B Kerber K Langa KM: Longitudinal patient-oriented outcomes in neuropathy: Importance of early detection and falls. Neurology. 2015;85(1):71-9. 26019191 10.1212/WNL.0000000000001714 4501944 F1000 Recommendation